NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZITUVIO (sitagliptin) by Biocon is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIO (sitagliptin) is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor approved in October 2023 for type 2 diabetes management. It works by inhibiting DPP-4 enzyme to increase incretin hormone levels, enhancing glucose-dependent insulin secretion and reducing glucagon secretion. This mechanism offers a glucose-dependent approach with a favorable hypoglycemia profile.
Growth8.4 years to LOE
Product is in growth phase with recent FDA approval, suggesting expanding commercial infrastructure and growing team investment in market development.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
Started Apr 2026
12 enrolled
Healthy Volunteers
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Bioequivalence Study of Sitagliptin/Metformin Extended-Release Tablets in Healthy Subjects
Started Feb 2023
76 enrolled
Healthy Volunteers
Semaglutide vs Sitagliptin
Started Oct 2022
58 enrolled
Liver Transplant; ComplicationsDiabetes MellitusNASH - Nonalcoholic Steatohepatitis+1 more
Worked on ZITUVIO at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.